| Title: |
Nutritional status with tirzepatide in obesity:A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials |
| Authors: |
Almandoz, Jaime P; Pickett-Blakely, Octavia; Tewksbury , Colleen; Stefanski, Adam; Gonsahn-Bollie, Sylvia; Dimitriadis, Georgios K; Murro, Ada Leticia; Cao, Dachuang; Meng, Qier; Neff, Lisa M |
| Source: |
Almandoz, J P, Pickett-Blakely, O, Tewksbury , C, Stefanski, A, Gonsahn-Bollie, S, Dimitriadis, G K, Murro, A L, Cao, D, Meng, Q & Neff, L M 2026, 'Nutritional status with tirzepatide in obesity : A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials', Obesity Pillars, vol. 17, 100248. https://doi.org/10.1016/j.obpill.2026.100248 |
| Publication Year: |
2026 |
| Collection: |
King's College, London: Research Portal |
| Description: |
Background: Nutritional deficiencies are common among people with obesity, before and during treatment, such as with very-low-calorie diets and metabolic/bariatric surgery. Obesity management medications (OMMs) can reduce appetite and dietary intake, potentially affecting nutritional status. The impact of OMMs on nutritional outcomes in people with obesity warrants further study. Methods: We conducted a post hoc analysis of available nutritional status-related data from the randomized, placebo-controlled, phase 3 SURMOUNT-1-4 trials of tirzepatide (N = 4726). Descriptive statistics were utilized to explore available nutritional status-related data from clinical trial reports, including investigator-reported treatment-emergent adverse events (TEAEs) based on 14 MedDRA preferred terms, chosen to identify cases of macronutrient malnutrition; investigator-reported vitamin deficiency-related TEAEs; biomarkers assessed systematically during the trials (albumin; total lymphocyte count [TLC]); reasons for early treatment discontinuation; and participants reaching body mass index (BMI) < 18.5 and < 22 kg/m2. Results: Investigators reported 3 of 14 TEAEs potentially related to macronutrient malnutrition. TEAE incidence of Abnormal loss of weight, Underweight, and Hypoalbuminemia was 0.03 %, 0.06 %, and 0.03 % with tirzepatide and 0 %, 0 %, and 0.06 % with placebo, respectively. Vitamin deficiency-related TEAEs were reported for 0.99 % and 1.07 % of tirzepatide- and placebo-treated participants, respectively. Albumin |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| DOI: |
10.1016/j.obpill.2026.100248 |
| Availability: |
https://kclpure.kcl.ac.uk/portal/en/publications/bcb6ddee-2ddf-48fb-9a0a-2761f9d473de; https://doi.org/10.1016/j.obpill.2026.100248; https://kclpure.kcl.ac.uk/ws/files/364113273/1-s2.0-S2667368126000045-main.pdf; https://www.scopus.com/pages/publications/105028301839 |
| Rights: |
info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.DE7A0F74 |
| Database: |
BASE |